PET imaging of nicotinic acetylcholine receptors in baboons with 18F-AZAN, a radioligand with improved brain kinetics

Journal of Nuclear Medicine

Volumn 53, Issue 1, 2012, Pages 121-129

  Kuwabara, Hiroto ^a   Wong, Dean F ^a   Gao, Yongjun ^a   Valentine, Heather ^a   Holt, Daniel P ^a   Ravert, Hayden T ^a   Dannals, Robert F ^a   Horti, Andrew G ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

18F AZAN; Baboon; Cytisine; nAChR; Nicotine; PET

Indexed keywords

2 (6 FLUORO 2,3' BIPYRIDIN 5' YL) 7 METHYL 7 AZABICYCLO[2.2.1]HEPTANE F 18; 8 AZAGUANINE; CYTISINE; FLUORINE 18; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA4BETA2; NICOTINIC RECEPTOR BLOCKING AGENT; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BABOON; BINDING AFFINITY; BRAIN FUNCTION; BRAIN REGION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG BINDING; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG SCREENING; DRUG SYNTHESIS; DRUG UPTAKE; ISOTOPE LABELING; MALE; NONHUMAN; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; RADIOACTIVITY; RECEPTOR BLOCKING; RECEPTOR OCCUPANCY;

2,2'-DIPYRIDYL; ALKALOIDS; ANIMALS; AZABICYCLO COMPOUNDS; AZOCINES; BRAIN; HEPTANES; KINETICS; LIGANDS; MALE; MODELS, BIOLOGICAL; NICOTINIC ANTAGONISTS; PAPIO; POSITRON-EMISSION TOMOGRAPHY; QUINOLIZINES; RADIOCHEMISTRY; RECEPTORS, NICOTINIC;

EID: 84855400620     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.092338     Document Type: Article

References (37)

1. Kellar KJ, Xiao Y. Neuronal nicotinic receptors: one hundred years of progress. In: Sibley DR, ed. Handbook of Contemporary Neuropharmacology. Vol. 1. Hoboken, NJ: Wiley-Interscience; 2007:108-131.
2. Paterson D, Nordberg A. Neuronal nicotinic receptors in the human brain. Prog Neurobiol. 2000;61:75-111. (Pubitemid 30100404)
3. Pimlott SL, Piggott M, Owens J, et al. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[125I]-a-85380. Neuropsychopharmacology. 2004;29:108-116. (Pubitemid 38068020)
4. Gotti C, Fornasari D, Clementi F. Human neuronal nicotinic receptors. Prog Neurobiol. 1997;53:199-237. (Pubitemid 27436001)
5. Villemagne VL, Musachio JL, Scheffel U. Nicotine and related compounds as PET and SPECT ligands. In: Arneric SP, Brioni JD, eds. Neuronal Nicotinic Receptors, Pharmacology and Therapeutic Opportunities. New York, NY: Johns Wiley & Sons; 1999:235-250.
6. Horti AG, Villemagne VL. The quest for Eldorado: development of radioligands for in vivo imaging of nicotinic acetylcholine receptors in human brain. Curr Pharm Des. 2006;12:3877-3900. (Pubitemid 44560700)
7. Sihver W, Langstrom B, Nordberg A. Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. Acta Neurol Scand Suppl. 2000;176: 27-33. (Pubitemid 32156167)
8. Horti AG, Wong DF. Clinical perspective and recent development of pet radioligands for imaging cerebral nicotinic acetylcholine receptors. PET Clin. 2009; 4:89-100.
9. Horti AG, Gao Y, Kuwabara H, Dannals RF. Development of radioligands with optimized imaging properties for quantification of nicotinic acetylcholine receptors by positron emission tomography. Life Sci. 2010;86:575-584.
10. Kimes AS, Chefer SI, Matochik JA, et al. Quantification of nicotinic acetylcholine receptors in the human brain with PET: bolus plus infusion administration of 2-[18F]F-A85380. Neuroimage. 2008;39:717-727. (Pubitemid 350117632)
11. 18F]fluoropyridin-2-yl)-5′-pyridinyl]-7- azabicyclo[2.2.1]heptane, a radiolabeled antagonist for cerebral nicotinic acetylcholine receptor (alpha4beta2-nAChR) with optimal positron emission tomography imaging properties. J Med Chem. 2008;51:4751-4764.
12. Brown LL, Kulkarni S, Pavlova OA, et al. Synthesis and evaluation of a novel series of 2-chloro-5-((1-methyl-2-(S)-pyrrolidinyl)methoxy)-3-(2-(4- pyridinyl) vinyl) pyridine analogues as potential positron emission tomography imaging agents for nicotinic acetylcholine receptors. J Med Chem. 2002;45: 2841-2849. (Pubitemid 34627654)
13. Black KJ, Snyder AZ, Koller JM, Gado MH, Perlmutter JS. Template images for nonhuman primate neuroimaging: 1. Baboon. Neuroimage. 2001;14:736-743. (Pubitemid 32801719)
14. Ashburner J, Friston KJ. High-dimensional image warping. In: Frackowiak RSJ, Friston KJ, Frith C, et al., eds. Human Brain Function. 2nd ed. New York, NY: Academic Press; 2003:673-694.
15. Ashburner J, Friston K. Rigid body registration. In: Frackowiak RSJ, Friston KJ, Frith C, et al., eds. Human Brain Function. 2nd ed. New York, NY: Academic Press; 2003:635-654.
16. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P. Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging. 1997;16:187-198. (Pubitemid 127762930)
17. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography. J Cereb Blood Flow Metab. 1991;11:735-744.
18. Innis RB, Cunningham VJ, Delforge J, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab. 2007; 27:1533-1539. (Pubitemid 47301451)
19. Abi-Dargham A, Laruelle M, Seibyl J, et al. SPECT measurement of benzodiazepine receptors in human brain with iodine-123-iomazenil: kinetic and equilibrium paradigms. J Nucl Med. 1994;35:228-238. (Pubitemid 24048309)
20. Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11 C-methyl]- (-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab. 1990; 10:740-747. (Pubitemid 20260955)
21. 11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab. 1995;15:152-165.
22. Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, Gunn RN. Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab. 2010;30:46-50.
23. Akaike H. A new look at statistical model identification. IEEE Trans Automat Contr. 1974;AU-19:716-722.
24. Sihver W, Nordberg A, Langstrom B, et al. Development of ligands for in vivo imaging of cerebral nicotinic receptors. Behav Brain Res. 2000;113: 143-157. (Pubitemid 30645552)
25. Volkow ND, Ding YS, Fowler JS, Gatley SJ. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia. Biol Psychiatry. 2001;49:211-220. (Pubitemid 32178430)
26. Brown L, Chefer S, Pavlova O, et al. Evaluation of 5-(2-(4-pyridinyl) vinyl)-6-chloro-3-(1-methyl-2-(S)-pyrrolidinylmethoxy)pyridine and its analogues as PET radioligands for imaging nicotinic acetylcholine receptors. J Neurochem. 2004;91:600-612. (Pubitemid 39431155)
27. 18F-nifene) in rodents and imaging by PET in nonhuman primate. Nucl Med Biol. 2006;33:295-304.
28. 18F]norchloro-fluoro- homoepibatidine. Synapse. 2008;62:205-218.
29. 18F-ZW-104: a new radioligand for imaging neuronal nicotinic acetylcholine receptors - in vitro binding properties and PET studies in baboons. J Nucl Med. 2009;50:1349-1355.
30. Gallezot JD, Bottlaender M, Gregoire MC, et al. In vivo imaging of human cerebral nicotinic acetylcholine receptors with 2-18F-fluoro-A-85380 and PET. J Nucl Med. 2005;46:240-247. (Pubitemid 43073430)
31. Wong DF, Yung B, Dannals RF, et al. In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428. Synapse. 1993;15:130-142. (Pubitemid 23311584)
32. Le Foll B, Chefer SI, Kimes AS, et al. Validation of an extracerebral reference region approach for the quantification of brain nicotinic acetylcholine receptors in squirrel monkeys with PET and 2-18F-fluoro-A-85380. J Nucl Med. 2007;48: 1492-1500. (Pubitemid 47397399)
33. Valette H, Bottlaender M, Doll F, et al. Imaging central nicotinic acetylcholine receptors in baboons with [18 F]fluoro-A-85380. J Nucl Med. 1999;40:1374-1380. (Pubitemid 29385648)
34. Valette H, Bottlaender M, Dolle F, Coulon C, Ottaviani M, Syrota A. Longlasting occupancy of central nicotinic acetylcholine receptors after smoking: a PET study in monkeys. J Neurochem. 2003;84:105-111. (Pubitemid 36182070)
35. Gotti C, Zoli M, Clementi F. Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol Sci. 2006;27:482-491. (Pubitemid 44251225)
36. Rollema H, Shrikhande A, Ward KM, et al. Pre-clinical properties of the alpha4-beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol. 2010;160:334-345.
37. Xiao Y, Kellar KJ. The comparative pharmacology and up-regulation of rat neuronal nicotinic receptor subtype binding sites stably expressed in transfected mammalian cells. J Pharmacol Exp Ther. 2004;310:98-107. (Pubitemid 38812700)